Japan Ingredient Sourcing
Active component / 機能性成分Food ingredientsPhase 2 · 2a

Soy Isoflavones & Equol

大豆イソフラボン・エクオール (Daizu Isoflavone / Equol)

femcare-wellnessffc-accepted
Send inquiry

Why source from Japan

Sourced from Nationwide (Otsuka Pharmaceutical Tokushima facility) with year-round Japanese supply, consistent quality, and traceability to the prefecture of origin.

Key spec

Glycine max (soybean); Lactococcus 20-92 (for Equol fermentation) source; FFC notification(s) on file; MOQ from 1 kg (concentrate) – 100 kg (lower-concentration grades).

Typical end-product

Femcare / yuragi-ki menopause-transition supplement (tablet, soft-gel, or jelly) — Midlife women's wellness; for S-equol products, positioning around 'directly delivers the bioactive metabolite regardless of gut microbiota' (per the EQUELLE® precedent).

At a glance

Suppliers listed
5 suppliers
Typical MOQ
1 kg (concentrate) – 100 kg (lower-concentration grades)
Regions of origin
Nationwide (Otsuka Pharmaceutical Tokushima facility)
Category
Food ingredients
Japan regulatory status
FFC-accepted for 'bone maintenance'; Tokuho approvals for legacy products
Japanese name
大豆イソフラボン・エクオール
Romaji
Daizu Isoflavone / Equol

About this ingredient

Soy isoflavones (aglycone and glycoside forms) and S-Equol produced by Lactococcus 20-92 fermentation. Otsuka Pharmaceutical's 'Equelle' (2014) was the world's first commercial fermented-soy Equol supplement. Only ~50% of Japanese (~30% of Western) women naturally produce Equol from dietary soy.

Regulatory status

JapanFFC-accepted for 'bone maintenance'; Tokuho approvals for legacy products
EUNovel food framework applies for isolated isoflavones
United StatesDSHEA dietary supplement; FDA-notified claims available

FAQ for OEM buyers

Q. What MOQs and lead times are typical for Japanese soy isoflavone and S-equol ingredients?

Sourcing reality varies sharply by ingredient form. Standardised aglycone-form soy isoflavone powders (e.g., koji-fermented preparations) are typically available in 1–10 kg trial lots and 50–500 kg commercial lots with 4–10 week lead times. Fermented S-equol concentrate is a much narrower market: Otsuka's EQUELLE® is the dominant commercial source in Japan and is sold as a finished consumer product, not as a bulk ingredient. Brands seeking S-equol as a bulk ingredient must work with the limited set of S-equol producers globally and should expect long lead times and IP-related restrictions on positioning.

Sources · Last reviewed: 2026-04-26

Industry-knowledge claim — not yet pinned to a single primary source

Q. What documentation should we expect from a soy isoflavone ingredient supplier?

Standard documentation includes: (1) per-lot CoA reporting individual isoflavone composition (daidzein, genistein, glycitein and their glycoside forms) by HPLC, total isoflavone content as aglycone-equivalent, residual solvents, heavy metals, microbiology, and allergen status (soy is a Codex-recognised major allergen and must be declared); (2) GMO status declaration — Identity-Preserved (IP) non-GMO soy is the norm for premium positioning, with supporting traceability paperwork; (3) for fermented preparations, the fermentation organism declaration and a process flow sufficient to confirm the absence of live bacteria in the finished material; (4) for S-equol products, a chiral purity statement (S- vs R-/racemic) since only S-equol is the biologically active form produced by gut bacteria.

Sources · Last reviewed: 2026-04-26

Q. Are non-GMO, kosher, halal, and organic options available for Japanese soy isoflavones?

Identity-Preserved (IP) non-GMO soy is the standard input for export-oriented Japanese soy isoflavone production; many Japanese suppliers source IP non-GMO soybeans from certified North American or domestic supply chains. Kosher and halal certifications are commonly available because the production process is plant-based with no animal-derived inputs, but should be confirmed per supplier and per ingredient grade. Organic-certified soy isoflavone powders exist but are rarer and command a premium — verify the certifying body (JAS / EU / USDA NOP) and confirm whether the certification covers the soy alone or the full extraction process.

Sources · Last reviewed: 2026-04-26

Industry-knowledge claim — not yet pinned to a single primary source

Q. What contract considerations are unique to soy isoflavones and S-equol?

Three areas warrant explicit contract treatment: (1) IP and trademark scope — EQUELLE®, Equelle®, ゆらぎ期®, Fuji-Flavone, AglyMax and similar marks are registered to specific companies and cannot be used by buyers without licensing; spell out in the supply agreement whether the supplier permits any reference to the upstream brand; (2) regulatory positioning — fix in writing which market(s) the buyer intends to sell into and confirm the supplier's documentation is sufficient for that market (EU Novel Food considerations, US DSHEA structure-function claim limits, China NMPA health-food filing, Korea MFDS health-functional-food review); (3) for FFC-eligible positioning in Japan, clarify whether the supplier provides systematic-review-ready clinical data or whether the buyer must build its own dossier.

Sources · Last reviewed: 2026-04-26

Q. What price-sensitivity factors drive soy isoflavone and S-equol pricing?

Per-kilo pricing is driven primarily by (1) form — direct fermented S-equol carries a multiple-order-of-magnitude premium over standardised soy isoflavone aglycone powder, which in turn carries a premium over crude soy extract; (2) standardisation — guaranteed minimum aglycone-equivalent content (e.g., 40% vs 10%) significantly affects unit price; (3) IP status — patented or branded ingredients (e.g., AglyMax®) may carry licensing components in the price; (4) raw-soy commodity pricing and IP non-GMO supply availability. Fluctuations in the global non-GMO soy market and any disruption in Japanese fermentation capacity can both move prices.

Sources · Last reviewed: 2026-04-26

Industry-knowledge claim — not yet pinned to a single primary source

Use cases

  • Femcare / yuragi-ki menopause-transition supplement (tablet, soft-gel, or jelly)

    Positioning
    Midlife women's wellness; for S-equol products, positioning around 'directly delivers the bioactive metabolite regardless of gut microbiota' (per the EQUELLE® precedent)
    Typical usage level
    Aglycone-form soy isoflavones: per-serving dose designed to keep supplement contribution within Japan's 30 mg/day aglycone-equivalent guidance. S-equol: typical reference per EQUELLE® product literature (10 mg S-equol per daily serving as a precedent dose).
    Formulation notes
    For Japanese-market positioning, aligning per-serving dose to the Food Safety Commission supplement-intake guidance is critical. For FFC notification, the dose, isoflavone form, and study population must mirror the underlying clinical evidence cited in the dossier. S-equol should be specified as the S-enantiomer; R- or racemic equol is not the biologically active form.

    Sources

  • Bone-maintenance functional supplement (FFC-positioned in Japan; structure-function claims in US)

    Positioning
    Postmenopausal bone metabolism support, leveraging the legacy Tokuho precedent and current FFC notifications for soy isoflavone bone endpoints
    Typical usage level
    Per-serving aglycone-equivalent dose set per the FFC dossier; formulators commonly co-formulate with calcium and vitamin D
    Formulation notes
    Bone-related claims in Japan must align with either an existing Tokuho approval or a self-filed FFC notification. In the US, claims must remain in DSHEA structure-function territory; specific disease (osteoporosis prevention) claims are not permitted without an FDA-authorised health claim. Co-formulation with calcium and vitamin D is conventional.

    Sources

  • Beauty drink / collagen-isoflavone jelly (Japan domestic)

    Positioning
    'Inner beauty' / skin-quality positioning, often paired with collagen peptide, placenta extract, or hyaluronic acid
    Typical usage level
    Aglycone-equivalent dose constrained by Japanese supplement-intake guidance; isoflavone serves as the headline functional ingredient with co-actives delivering complementary positioning
    Formulation notes
    Soy isoflavone is moderately heat-stable but should be added after the high-temperature dissolving step where possible. Match the chosen isoflavone form (aglycone vs glycoside) to the target absorption kinetics and to any FFC evidence the SKU intends to lean on.

    Sources

  • S-equol-direct supplement for non-equol-producing markets (e.g., Western women)

    Positioning
    Bypasses the gut-microbiota requirement that limits equol exposure to roughly 20–35% of Western adults
    Typical usage level
    Reference precedent: 10 mg S-equol per daily serving (per EQUELLE® product literature)
    Formulation notes
    Critical to specify the S-enantiomer rather than racemic equol. Brands launching outside Japan must clear country-specific regulatory paths: in the US, DSHEA structure-function claims; in the EU, isolated S-equol may engage Novel Food considerations and should be cleared with regulatory counsel before launch. Avoid implied therapeutic claims for menopausal symptoms; keep claim language to wellness / quality-of-life territory unless supported by an authorised claim.

    Sources

Looking for alternatives?

Common reasons buyers swap to a different ingredient — and what we'd suggest based on this ingredient's profile.

When does it make sense to swap an ingredient? Read the swap guide →

Japanese suppliers

Inquire about Soy Isoflavones & Equol

Disclaimer

Japan Ingredient Sourcing Platform introduces overseas buyers to Japanese ingredient manufacturers. The platform is an information service only and is not a party to any purchase, supply, or manufacturing contract between buyer and seller.

Information shown — including company details, product descriptions, regions of origin, minimum order quantities, lead times, certifications, and regulatory references — is compiled primarily from publicly available sources and manufacturer websites. Specifications change without notice; buyers are expected to verify current specifications, pricing, certification status, and regulatory compliance directly with each manufacturer before placing orders or signing contracts.

The platform operator is not licensed to provide legal, regulatory, customs, tax, or professional advice. References to third-party companies, products, certifications, trademarks, and geographical indications (GI) are factual and do not imply endorsement, sponsorship, or affiliation. All trademarks are the property of their respective owners.

Last updated: 2026-04-24

Inquire about Soy Isoflavones & Equol